Medovate news

Medovate is delighted to be sponsoring the European Society for the 4th ESRA Residents & Trainees Workshop event, taking place at the Hospital das Forças Armadas on the 1^st and 2^nd April in Porto, Portugal.

As well as being an Industry Partner, Medovate will also be showcasing the 

Medovate has announced that it has entered into an agreement with Mercury Medical® for primary distribution of the FDA-cleared device SAFIRA® (SAFer Injection for Regional Anesthesia) across the whole of the United States (US).

The agreement also includes the newly launched SAFIRA&re

When Medovate was spun out of the National Health Service (NHS) in 2017, one of the key priorities was to ensure that each medical device the company developed added real value to patient safety.

The company mission is to “improve patient care and safety by supplying innovative Medtech solutions inspired by clinicians and developed in partnership with the NHS.”

Through a unique approach and business model, Medovate is working with NHS clinical inventors to develop

Medovate is delighted to be joining the Association of British HealthTech Industries (ABHI) US Accelerator 2022 cohort. The dynamic Cambridge-based development company, who are helping to bring to life pioneering medical devices, is participating in the programme for a second year running.

Now in its fifth year, the ABHI US Accelerator, conducted in partnership with the Dell Medical School in Austin, Texas, supports UK medical device, diagnostic